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Summary The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in
conjuction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous
concentrations of 5FU are lower and plasma clearance values higher following intrahepatic arterial administra-
tion compared with a similar dose administered by intravenous infusion over both 2 h and 24 h. For the 2 h
drug infusions, plasma 5FU concentrations following co-treatment with angiotesin II and microspheres via the
hepatic artery were intermediate between those of arterial and venous infusions of 5FU alone. There was a
trend towards the peak plasma drug concentrations and the area under the plasma concentration-time curve
(AUC) being significantly lower following co-treatment with angiotensin II and microspheres compared with
intra-arterial and intravenous infusions of 5FU over 24h. Co-administration of 5FU, angiotensin II and
microspheres via the hepatic artery may reduce drug exposure in the systemic compartment and therefore may
increase the therapeutic ratio of 5FU administration via the hepatic artery.
Systemic chemotherapy for colorectal hepatic metastases is
associated with high toxicity and poor therapeutic outcome.
Although there is a lack of data supporting its efficacy in
prolonging survival (Malik et al., 1988), the popularity
of regional chemotherapy for neoplastic liver disease is con-
tinuing to gather momentum. The rationale behind regional
chemotherapy is that tumour exposure to drug is increased,
whereas that of the systemic circulation is reduced compared
to anticancer drug administration via the hepatic artery. This
effect could be further amplified with greater extraction of
the drug on first pass following prolongation of the intra-
arterial infusion (Stevens, 1983).
If we assume that toxicity relates to the amount of drug in
the systemic vascular compartment, toxicity should be greatly
reduced during regional chemotherapy. We have previously
observed that there is no reduction in systemic drug exposure
when 5FU is administered via the hepatic artery in a bolus
dose of 1 g (Goldberg et al., 1988a). Although there is
evidence to suggest that the regional co-administration of
microspheres (diameter 40 l.m) with drug can increase drug
uptake by the liver and cause a corresponding reduction in
systemic drug levels (Gyves et al., 1983), we were again
unable to demonstrate a reduction in systemic drug levels
when albumin microspheres were co-administered with a
bolus dose of 5FU (Goldberg et al., 1988a).
Regional administration of the vaso-active agent angio-
tensin II has been shown to increase tumour blood-flow
temporarily (Sasaki et al., 1985) and this mechanism may
have applications in regional therapy (Goldberg et al., 1987a,
b) in that it might prove possible to increase microsphere
delivery to the tumour. The additional of angiotensin II had
no effect on systemic drug levels as assessed by area under
the plasma concentration-time curve, half-life of the drug in
plasma and drug clearance of bolus-injected 5FU in our
earlier study (Goldberg et al., 1988a).
In the present study, results following prolonged drug
infusions in patients with hepatic metastases from colorectal
primary tumours are reported. Two drug infusion durations
were studied, 2 h (consistent with outpatient therapy) and
24 h (primarily an in-patient treatment).
Materials and methods
Seven patients with advanced colorectal hepatic metastases
and indwelling hepatic arterial perfusion catheters were
studied. Estimations of the percentage of hepatic replacement
of liver parechyma by tumour were based on 99'Tc tin colloid
imaging performed before the study. Baseline shunting was
estimated for each patient on two separate occasions before
commencing the present study (Goldberg et al., 1987b).
Pharmacokinetic studies were performed for each of the
treatments listed. The studies in each series were performed in
random order and completed within an 8 week period. Treat-
ment was given at weekly intervals. I.v. 5FU: (a) Intravenous
infusion of 30 mg kg-' body weight of 5FU over 2 hours. (b)
Intravenous infusion of 1 g of 5FU over 24 h. I.a. 5FU: (a)
Intrahepatic arterial infusion of 30 mg kg-' of 5FU over 2 h.
(b) Intrahepatic arterial infusion of I g of 5FU over 24 h. I.a.
All; AMS; 5FU: (a) Intrahepatic arterial infusion of angio-
tensin II (AII) 10iLg min-' for 100 s, bolus injection of
albumin microspheres 300 mg (AMS), infusion of 5FU,
30 mg kg-' over 2 h. (b) Intrahepatic arterial infusion of
angiotensin II (AII) 10 ltg min-' for 100 s, bolus injection of
albumin microspheres (AMS), infusion of 5FU, 1 g over 24 h.
Albumin microspheres with a diameter of between 20 and
40lm were prepared as described previously (Goldberg et
al., 1988a; Lee et al., 1981; Willmott et al., 1985) and
administered in 300 mg doses containing between 60 and 90
million particles.
Angiotensin II was infused for 100 s into the hepatic artery
catheter followed immediately by a bolus injection of micro-
spheres, then 5FU infusion was started. Each patient received
5FU at two infusion rates, over 2 h and 24h on separate
occasions. Systemic blood-pressure was continually monitor-
ed during angiotensin II infusion. Transient rises in blood
pressure of up to 50 mmHg were noted, but were not
associated with any neurological signs or symptoms. More
prolonged infusions of angiotensin II were not considered
feasible, as they would be associated with prolonged periods
of hypertension.
Blood samples (10 ml) were withdrawn from a cannula
positioned in an ante-cubital vein and collected into lithium
heparin tubes before commencement of each study and at
intervals during the period of drug infusion (0, 5, 15,
30, 60, 90, 105, 120 min for the 2 h infusions; 0, 2, 6, 8, 12,
24 h for the 24 h infusions). White cell and platelet counts
were checked before and one week after each study. Blood
samples for drug assay were centrifuged (2,000 r.p.m. for
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15 min) and the plasma separated and stored at -20°C while
awaiting analysis. Concentrations of SFU in plasma taken
during the 2 h infusion were measured by a sensitive and
specific HPLC method (Christophidis et al., 1979) with inter-
and intra-assay coefficients of variation of between 5 and
10%.
Concentrations of 5FU were measured in plasma during
the 24 h study by gas chromatography mass spectrometry
(GC-MS), because the drug concentrations were frequently
below the lower limit of detection for the HPLC method.
A new derivatisation procedure was developed for this
study. '5N2-5FU (50ng in 50ttl acetonitrile) was added to
0.5 ml plasma, acidified with acetic acid (pH 5) and shaken
with diethyl ether/isopropanol (4:1, 5 ml) on a vortex mixer.
Solvent was removed by flash evaporation and the extraction
residue taken up in ethyl acetate (1 ml) and transferred
to a reactivial. The ethyl acetate was removed under a stream
of nitrogen and the residue dissolved in acetonitrile (50gd).
Ditrifluoromethylbenzylbromide (10pl) and triethylamine
(10Jl) were then added to the solution and the mixture left
at room temperature (15 min). The mixture was diluted with
ethyl acetate (100 tl) followed by hexane (900 pl) to precip-
itate triethylamine bromide and passed through Sephadex
LH20 (about 3 cm in a Pasteur pipette), and the LH20
washed with a further I ml of hexane. The solvent was
removed under a stream ofnitrogen and the residue dissolved
in ethyl acetate (0.5 ml). An aliquot of the final solution
(2 ,.l) was injected into the GC-MS.
GC-MS was performed using a Hewlett-Packard 5988A
GC-MS instrument in the negative ion chemical ionisation
mode with methane as the reagent gas. The GC was fitted
with a 12 m x 0.25 mm i.d. aluminium clad BP-I capillary
column (SGE) and the oven was programmed as follows:
80°C (I min) then 20°C per min to 300°C, injector temper-
ature was 250°C. 5FU was quantitated by comparing the
area ratio for the ions m/z 355 and 357 arising respectively
from 5FU and the '5N2-5FU internal standard with ratios for
the ions obtained from a 50 ng + 50 ng standard mixture of
5FU and internal standard. Before the analysis of biological
samples by this procedure the linearity of the method over
the concentration range under investigation was established
by mixing varying amounts of SFU into samples of plasma
containing a fixed amount (50 ng) of '5N2-5FU.
Plasma concentration-time curves for individual patients
were computer fitted to the equations appropriate for an
infusional one-compartment model using an in-house pro-
gramme based on the Marquhardt algorithm (Bevington et
al., 1969). Statistical comparisons were performed using
paired Student's t test with the Bonferroni correction where
appropriate.
Results
Tin colloid imaging showed that all patients had advanced
metastatic liver disease (two patients had between 10 and
25% hepatic replacement by tumour, and five had between
25 and 50%) Baseline shunting was estimated at less than
3% on two or more occasions in each patient. The various
treatments were well tolerated and there was no difference in
gastrointestinal or haematological toxicity.
Pharmacokinetic parameters are summarised in Tables I
and II. Following 2 h infusions, the plasma AUC was lower
(P<0.05) and plasma clearance higher (P<0.05), for intra-
arterial SFU compared with intravenous 5FU. Intra-arterial
treatment with microspheres and angiotensin II produced
AUC and clearance values which were intermediate between
intra-arterial infusion alone and intravenous infusions.
In the 24 h infusions, there was an increasing trend in drug
clearance, and a falling trend in AUC with intravenous SFU,
intra-hepatic 5FU, and intra-hepatic arterial drug with
angiotensin II and microspheres respectively (Table II). There
were highly significant differences between the intravenous
and intra-arterial combination infusion parameters (Cmax,
P<0.001; AUC, P<0.003; clearance, P<0.01), and
Table I Pharmacokinetic studies of intra-venous and intra-hepatic
arterial infusion of 5FU (30 mg kg-' body weight over 2 h) with and
without angiotensin II and albumin microspheres in patients with
advanced colorectal hepatic metastases
n C. AUC Clearance
(pg min- ) (ftgml-Zmin- )(Imin- )
i.v. 5FU 7 10.5 4.8a 1200 262a 1.75+0.23a
i.a. 5FU 7 7.9±42a 788±104a 2.66±0.35a
i.a. All; AMS; 5FU 7 9.4± 3.1 1068 179 1.90±0.29
aComparison ofintra-arterial with intra-venousdrugadministration.
P<0.05 (Student's t test). Cm. = maximum drugconcentration within
plasma; AUC = area under the plasma 5FU concentration-time curve
(values expressed as mean±s.d.).
Table II Pharmacokinetic studies of intra-venous and intra-arterial
infusion of 5FU (1 g over 24 h) with and without angiotensin II and
albumin microspheres in patients with advanced colorectal hepatic
metastases
C..<x AUC
(ng ml-) (4Lgmlh min')
Clearance
(Imin-')
i.v. 5FU 6 121+41a,b 54± 18b 18±7a,b
i.a. 5FU 6 48±32a 24±18 42±27a
i.a. All; AMS; 5FU 6 27±20b 12±9b 84±6lb
aCompanson ofintra-arterial with intra-venous drug administration.
P<0.05 (Student's t test). bComparison ofintra-arterial combination
treatment (5FU, All, AMS) with intravenous drug infusion, P< 0.05
(Student's t test). CGax = maximum drug concentration within plasma;
AUC = area under the plasma 5FU concentration-time curve (values
expressed as mean±s.d.).
between intravenous and hepatic arterial C.. and clearance
(P<0.02 and P<0.03 respectively). The differences between
hepatic arterial infusion of the drug alone, and the combina-
tion infusion did not reach significance, however.
Discussion
With the development of reliable drug infusion devices, the
safe and convenient administration of a drug by continuous
infusion has become possible. The rationale behind con-
tinuous regional infusion of drug is that it might increase
the concentration of drug in the organ harbouring metastatic
tumour deposits, while reducing the systemic exposure and
hence toxicity. Because intra-arterial chemotherapy has
become technically feasible and can be offered to a group of
patients with otherwise very limited treatment options and a
poor prognosis, its popularity has increased. However, it is
also a very costly treatment option which requires operative
placement of the hepatic arterial catheter. It is therefore
important to evaluate potential therapeutic advantages as
thoroughly as possible at an early stage.
In a previous study, we compared the plasma concentra-
tion-time profiles of bolus SFU administered intravenously,
or via the hepatic artery, combined with microspheres or
combined with angiotensin II and microspheres. No
difference in systemic drug exposure could be demonstrated
between the treatment regimes (Table III) (Goldberg et al.,
1988a).
The most likely explanation for this was the existence of a
saturable mechanism of SFU extraction by the liver. Drug
administered by bolus injection might exceed the capacity of
the tumour-bearing liver to take up the drug and allow a
larger proportion of the chemotherapeutic agent to enter the
systemic circulation.
It was a logical step to increase the duration of infusion of
SFU to attempt to increase drug extraction. The infusion
rates used in this study were chosen to represent an out-
patient (2 h infusion) versus an inpatient (24 h infusion)
treatment.
It is clear that the hepatic arterial infusion of SFU
significantly reduces systemic exposure, as manifested by
lower peak plasma concentrations and AUC, compared with
intravenous infusion. Drug clearance values for bolus, 2 and
24 h infusions of SFU are tabulated in Table III and bear out5 FU PHARMACOKINETICS 915
Table III Comparison of clearance of 5FU from plasma after bolus
injection, 2 h and 24 h infusion intravenously and intra-arterially (with
and without angiotensin II and albumin microspheres)
Clearance of Clearance of Clearance of
5FU (Bolus 5FU (2h 5FU (24 h
injection) infusion) infusion)
n (Imin') n (Imin'-) n (Imini-)
i.v. 9 0.94±0.3a 7 1.75±0.2a 6 18.4±6.5a
i.a. 9 0.81±0.2a 7 2.66±0.4a 6 42.0±27.1a
i.a. All; AMS; 5 0.78±0.3 7 1.90±0.3 6 84.0±61.3
5FU
ap<0.05 (Student's t test).
this point. Plasma clearance of 5FU is significantly higher
following intra-hepatic arterial infusion and tends to rise as
the duration of the infusion increases.
The reasoning behind co-treatment with microspheres and
angiotensin II is to deposit the microspheres within the
tumour vasculature (the tumour/normal blood-flow ratio is
enhanced by angiotensin II), thereby slowing the blood-flow
through the tumour in order to increase the drug extraction
rate. It is difficult to interpret our pharmacokinetic data on
this point since there was a trend of falling AUC for the
hepatic arterial infusion of 5FU with microspheres and
angiotensin II (although this did not reach statistical
significance), but not for the 2 h infusion.
There were no correlations between the pharmacokinetic
parameters and full blood-count one week after treatment.
There was no significant myelosuppression, and no treatment
delays were incurred due to toxicity. We would conclude that
a 24 h hepatic arterial infusion of 5FU plus angiotensin II
and microspheres might increase the therapeutic ratio of 5FU
and allow the potential for dose escalation. It would be
interesting to measure 5FU concentrations in the hepatic
metastatic tumour under these different conditions, but this
would require biopsy of tumour nodules, which is not always
a practicable procedure.
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